PPD Named to ‘Best Workplaces in Greater China’ for Second Consecutive Year
December 07 2021 - 9:00AM
Business Wire
PPD, Inc. (Nasdaq: PPD) was named one of the “Best Workplaces in
Greater China™ 2021” by Great Place to Work® for successfully
creating an inclusive workplace experience for employees.
PPD has more than 20 years of experience in the Asia-Pacific
region, including providing a broad range of clinical development
and laboratory services in Greater China. This is the second year
PPD has received this recognition from Great Place to Work®, a
global authority on high-trust, high-performance workplace
cultures.
“We remain committed to providing a healthy and open work
environment for our employees, and this award shows that we
continue to be successful in our efforts for yet another year,”
said Ding Ming, Ph.D., vice president and general manager of PPD’s
China operations. “PPD’s reputation in Greater China is a direct
reflection of our inclusive culture, robust employee relations and
attractive benefits. We continue to raise the bar as a preferred
employer in this competitive market, and we remain dedicated to
cultivating a diverse work atmosphere to attract and recruit highly
qualified candidates to deliver quality results for our
customers.”
Great Place to Work® surveyed more than 150 companies in
Mainland China, Hong Kong and Taiwan to assess employees'
perceptions of leadership, organizational culture and trust. PPD
was one of 61 companies named to the 2021 list.
PPD continues to expand in Asia-Pacific to serve local and
global customers, with operations across the region. PPD provides a
broad range of Phase I-IV services in Asia-Pacific, including
clinical monitoring, project management, regulatory affairs,
pharmacovigilance, data management and patient recruitment. Earlier
this year, PPD opened its new multipurpose laboratory in Suzhou,
China, to provide bioanalytical, biomarker and vaccine laboratory
services to support Western and China-based pharmaceutical and
biotech companies managing China research studies.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and
lifecycle management services. Our customers and partners include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With more than 30,000 professionals
worldwide, PPD has conducted clinical trials in more than 100
countries to help customers deliver life-changing therapies to
improve health. We apply innovative technologies, therapeutic
expertise and a firm commitment to quality to bend the cost and
time curve of drug development and optimize value. For more
information, visit www.ppd.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; the risks related to the proposed merger of
PPD by Thermo Fisher Scientific Inc.; and other factors disclosed
under the “Risk Factors” section in our periodic reports filed with
the Securities and Exchange Commission (SEC), including our latest
Annual Report on Form 10-K and Quarterly Report on form 10-Q, which
are available on our website at https://investors.ppd.com or the
SEC’s website at www.sec.gov. We assume no obligation and disclaim
any duty to revise or update any forward-looking statements, or
make any new forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211207005682/en/
PPD Contacts Media: Nadine Maeser +1 910 558 4779
media@ppd.com
Investors: Tracy Krumme +1 910 558 4186 investors@ppd.com
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Aug 2023 to Aug 2024